Tris Pharma`s Generic Cyproheptadine Hydrochloride Receives Approval in the U.S.
Quagen`s Generic Cyproheptadine Hydrochloride Receives Approval in US
Beximco Pharms Generic Cyproheptadine Hydrochloride Receives Approval in US
Invatech Pharma's Generic Cyproheptadine Hydrochloride Receives in US
Strides Pharma`s Generic Cyproheptadine Hydrochloride Receives Approval In US
Silarx Pharm’s Generic Cyproheptadine Hydrochloride Receives Approval In US
PHILADELPHIA, July 14, 2017 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Cyproheptadine Hydrochloride Syrup (Cyproheptadine Hydrochloride Oral Solution, USP) 2 mg/5 mL, the therapeutic equivalent to the reference standard drug, Cyproheptadine Hydrochloride Syrup (Cyproheptadine Hydrochloride Oral Solution USP) by Lyne Laboratories, Inc. The product was previously marketed under the brand name Periactin® Syrup, 2 mg/5 mL of Merck and Co., Inc. For the 12 months ended May 2017, total U.S. sales of Cyproheptadine Hydrochloride Syrup, 2 mg/5 mL, at Average Wholesale Price (AWP) were approximately $6 million, according to IMS.
NEW DELHI: Drug firm Zydus Cadila today said it has received approval from the US health regulator to market antihistamine Cyproheptadine Hydrochloride tablets in the US market.
Apnar's Generic Cyproheptadine Hcl Receives Approval In US
Newgen Pharms's Generic Amantadine Hcl Receives Approval In US